Review
BibTex RIS Cite

İNFANTİL HEMANJİYOM TEDAVİSİNDE BETA BLOKERLER

Year 2018, Volume: 3 Issue: 1, 1 - 9, 06.04.2018

Abstract

İnfantil Hemanjiyom (İH), infantil çağın en sık görülen tümörüdür. İH, endotel hücrelerinin anormal proliferasyonu ve anormal damar yapısı ile karakterize lezyonlarla seyreden vasküler bir neoplazidir. Vasküler anomaliler sınıflandırmasında benign vasküler tümörler arasında yer almaktadır. Doğum sonrası dönemde proliferatif fazın bulunması İH için karakteristik bir bulgudur. Proliferatif fazın sonrasında, involüsyon ve stabilizasyon fazları gözlenir. Tipik olarak progresif spontan involüsyon fazında tümöral lezyonlar yıllar içinde kendiliğinden gerilemekte, sıklıkla herhangi bir tedaviye ihtiyaç duyulmamaktadır. Ancak kanama, ülserasyon, kalıcı estetik deformite ve fonksiyon bozukluğu geliştiği durumlarda tıbbi müdahale gerekebilir. Bu tür komplike vakalarda uygulanan tedavi stratejisi, 2008 yılından sonra tamamen değişmiş olup, nonselektif beta blokerler tedavide ilk sırada verilecek ilaç olarak listede yerini almıştır. Bu derlemede, İH'nin genel özellikleri ve tedaviye son yıllarda
35
GDD Güncel Dermatoloji Dergisi
katılan beta bloker ilaçların etkisi, dozları, süresi ve yan etkileri hakkında bilgi verilmesi amaçlanmıştır.

References

  • 1. Darrow A, Greene AK, Mancini AJ, ET AL. Diagnosis and management of infantile hemangioma. Pediatrics 2015; 136: 1060-104.
  • 2. https://www.issva.org/UserFiles/file/Classifications-2014-Final.pdf
  • 3. Grzesik P, Wu JK. Current perspectives on the optimal management of infantile hemangioma. Pediatric Health Med Ther 2017; 8: 107-16.
  • 4. Cheng CE, Friedlander SF. Infantile hemangiomas, complications and treatments. Semin Cutan Med Surg 2016; 35: 108-16.
  • 5. Haggstrom AN, Drolet BA, Baselta E, et al. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr 2007; 150: 291-4.
  • 6. Hoeger PH, Harper JI, Baselda E, et al. Treatment of infantile haemangiomas: recommendations of a European expert group. Eur J Pediatr 2015; 174: 855-65.
  • 7. Léauté-Labréze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet 2017; 390: 85-94.
  • 8. Rotter A, de Oliveira ZNP. Infantile hemangioma: pathogenesis and mechanisms of action of propranolol. J Dtsch Dermatol Ges 2017;15: 1185-90.
  • 9. Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. British Journal of Dermatology 2010; 163: 269-74.
  • 10. Baselda Torres E, Bernabeu Wittel J, van Esso Arbolave DL, et al. Spanish consensus on infantile haemangioma. An Pediatr 2016; 85: 256-65.
  • 11. Zimmermann AP, Wiegand S, Werner JA, et al. Propranolol therapy for infantile haemangiomas: review of the literature. Int J Pediatr Otorhinolaryngol 2010; 74; 338-42.
  • 12. Adams DM, Ricci KW. Infantile Hemangiomas in the Head and Neck Region Otolaryngol Clin North Am 2018; 51: 77–87.
  • 13. Ji Y, Chen S, Xu C, et al. The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action. Br J Dermatol. 2015; 172: 24-32.
  • 14. Restrepo R, Palani R, Cervantes LF, et al. Hemangiomas revisited: the useful, the unusual and the new. Part 2: endangering hemangiomas and treatment. Pediatr Radiol 2011; 41: 905-15.
  • 15. Lee KC, Bercovitch L. Update on infantile hemangiomas. Semin Perinatol 2013; 37: 49-58.
  • 16. Menapace D, Mitkoy M, Towbin R, Hogeling M. The changing face of complicated infantile hemangioma treatment. Pediatr Radiol 2016; 46: 1494-506.
  • 17. Pineda IF, Williams R, Laureano LO, et al. Cardiovascular drugs in the treatment of infantile hemangioma. World J Cardiol 2016; 8: 74-80.
  • 18. Painter SL, Hildebrand GD. Review of topical beta blockers as treatment for infantile hemangiomas. Survey of Ophthalmology 2016; 61: 51-8.
  • 19. Püttgen K, Lucky A, Adams D, et al. Topical timolol maleate treatment of infantile hemangiomas. Pediatrics 2016; 138: 1-9.
  • 20. Burkey BW, Jacobs JA, Aziz H. Temperature instability in an infant treated with propranolol for infantile hemangioma. J Pediatr Pharmacol Ther 2017; 22: 124-7.
  • 21. Bayart CB, Tamburro JE, Vidimos AT, et al. Atenolol versus propranolol for treatment of infantile hemangiomas during the proliferative phase: a retrospective noninferiority study. Pediatr Dermatol 2017; 34: 413-21.
  • 22. Kado M, Shimizu A, Matsumura T, et al. Successful treatment of infantile hemangiomas with propranolol in low-birth-weight infants. J Craniofac Surg 2017; 28: 789-93.
  • 23. Li LL, Yan L, Luo MX, et al. Propranolol in the treatment of infantile hemangiomas: a meta-analysis in Chinese patients. Pediatric Dermatology 2015; 32: 210-4.
  • 24. Zheng L, Li Y.Effect of topical timolol on response rate and adverse events in infantile hemangioma: a meta-analysis. Arch Dermatol Res 2018 Jan 23. doi: 10.1007/s00403-018-1815-y. [Epub ahead of print].
  • 25. Chan H, McKay C, Adams S, et al. RCT of timolol maleate gel for superficial infantile hemangiomas in 5- to 24-week-olds. Pediatrics 2013; 131:e1739-47.
  • 26. Ovadia SA, Landy DC, Cohen ER, et al. Local administration of β-blockers for infantile hemangiomas: a systematic review and meta-analysis. Ann Plast Surg 2015; 74: 256-62.
Year 2018, Volume: 3 Issue: 1, 1 - 9, 06.04.2018

Abstract

References

  • 1. Darrow A, Greene AK, Mancini AJ, ET AL. Diagnosis and management of infantile hemangioma. Pediatrics 2015; 136: 1060-104.
  • 2. https://www.issva.org/UserFiles/file/Classifications-2014-Final.pdf
  • 3. Grzesik P, Wu JK. Current perspectives on the optimal management of infantile hemangioma. Pediatric Health Med Ther 2017; 8: 107-16.
  • 4. Cheng CE, Friedlander SF. Infantile hemangiomas, complications and treatments. Semin Cutan Med Surg 2016; 35: 108-16.
  • 5. Haggstrom AN, Drolet BA, Baselta E, et al. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr 2007; 150: 291-4.
  • 6. Hoeger PH, Harper JI, Baselda E, et al. Treatment of infantile haemangiomas: recommendations of a European expert group. Eur J Pediatr 2015; 174: 855-65.
  • 7. Léauté-Labréze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet 2017; 390: 85-94.
  • 8. Rotter A, de Oliveira ZNP. Infantile hemangioma: pathogenesis and mechanisms of action of propranolol. J Dtsch Dermatol Ges 2017;15: 1185-90.
  • 9. Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. British Journal of Dermatology 2010; 163: 269-74.
  • 10. Baselda Torres E, Bernabeu Wittel J, van Esso Arbolave DL, et al. Spanish consensus on infantile haemangioma. An Pediatr 2016; 85: 256-65.
  • 11. Zimmermann AP, Wiegand S, Werner JA, et al. Propranolol therapy for infantile haemangiomas: review of the literature. Int J Pediatr Otorhinolaryngol 2010; 74; 338-42.
  • 12. Adams DM, Ricci KW. Infantile Hemangiomas in the Head and Neck Region Otolaryngol Clin North Am 2018; 51: 77–87.
  • 13. Ji Y, Chen S, Xu C, et al. The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action. Br J Dermatol. 2015; 172: 24-32.
  • 14. Restrepo R, Palani R, Cervantes LF, et al. Hemangiomas revisited: the useful, the unusual and the new. Part 2: endangering hemangiomas and treatment. Pediatr Radiol 2011; 41: 905-15.
  • 15. Lee KC, Bercovitch L. Update on infantile hemangiomas. Semin Perinatol 2013; 37: 49-58.
  • 16. Menapace D, Mitkoy M, Towbin R, Hogeling M. The changing face of complicated infantile hemangioma treatment. Pediatr Radiol 2016; 46: 1494-506.
  • 17. Pineda IF, Williams R, Laureano LO, et al. Cardiovascular drugs in the treatment of infantile hemangioma. World J Cardiol 2016; 8: 74-80.
  • 18. Painter SL, Hildebrand GD. Review of topical beta blockers as treatment for infantile hemangiomas. Survey of Ophthalmology 2016; 61: 51-8.
  • 19. Püttgen K, Lucky A, Adams D, et al. Topical timolol maleate treatment of infantile hemangiomas. Pediatrics 2016; 138: 1-9.
  • 20. Burkey BW, Jacobs JA, Aziz H. Temperature instability in an infant treated with propranolol for infantile hemangioma. J Pediatr Pharmacol Ther 2017; 22: 124-7.
  • 21. Bayart CB, Tamburro JE, Vidimos AT, et al. Atenolol versus propranolol for treatment of infantile hemangiomas during the proliferative phase: a retrospective noninferiority study. Pediatr Dermatol 2017; 34: 413-21.
  • 22. Kado M, Shimizu A, Matsumura T, et al. Successful treatment of infantile hemangiomas with propranolol in low-birth-weight infants. J Craniofac Surg 2017; 28: 789-93.
  • 23. Li LL, Yan L, Luo MX, et al. Propranolol in the treatment of infantile hemangiomas: a meta-analysis in Chinese patients. Pediatric Dermatology 2015; 32: 210-4.
  • 24. Zheng L, Li Y.Effect of topical timolol on response rate and adverse events in infantile hemangioma: a meta-analysis. Arch Dermatol Res 2018 Jan 23. doi: 10.1007/s00403-018-1815-y. [Epub ahead of print].
  • 25. Chan H, McKay C, Adams S, et al. RCT of timolol maleate gel for superficial infantile hemangiomas in 5- to 24-week-olds. Pediatrics 2013; 131:e1739-47.
  • 26. Ovadia SA, Landy DC, Cohen ER, et al. Local administration of β-blockers for infantile hemangiomas: a systematic review and meta-analysis. Ann Plast Surg 2015; 74: 256-62.
There are 26 citations in total.

Details

Primary Language Turkish
Journal Section Güncel Derlemeler
Authors

Ebru Çelik This is me

Asena Çiğdem Doğramacı

Publication Date April 6, 2018
Published in Issue Year 2018 Volume: 3 Issue: 1

Cite

APA Çelik, E., & Doğramacı, A. Ç. (2018). İNFANTİL HEMANJİYOM TEDAVİSİNDE BETA BLOKERLER. Güncel Dermatoloji Dergisi, 3(1), 1-9.
AMA Çelik E, Doğramacı AÇ. İNFANTİL HEMANJİYOM TEDAVİSİNDE BETA BLOKERLER. GDD. April 2018;3(1):1-9.
Chicago Çelik, Ebru, and Asena Çiğdem Doğramacı. “İNFANTİL HEMANJİYOM TEDAVİSİNDE BETA BLOKERLER”. Güncel Dermatoloji Dergisi 3, no. 1 (April 2018): 1-9.
EndNote Çelik E, Doğramacı AÇ (April 1, 2018) İNFANTİL HEMANJİYOM TEDAVİSİNDE BETA BLOKERLER. Güncel Dermatoloji Dergisi 3 1 1–9.
IEEE E. Çelik and A. Ç. Doğramacı, “İNFANTİL HEMANJİYOM TEDAVİSİNDE BETA BLOKERLER”, GDD, vol. 3, no. 1, pp. 1–9, 2018.
ISNAD Çelik, Ebru - Doğramacı, Asena Çiğdem. “İNFANTİL HEMANJİYOM TEDAVİSİNDE BETA BLOKERLER”. Güncel Dermatoloji Dergisi 3/1 (April 2018), 1-9.
JAMA Çelik E, Doğramacı AÇ. İNFANTİL HEMANJİYOM TEDAVİSİNDE BETA BLOKERLER. GDD. 2018;3:1–9.
MLA Çelik, Ebru and Asena Çiğdem Doğramacı. “İNFANTİL HEMANJİYOM TEDAVİSİNDE BETA BLOKERLER”. Güncel Dermatoloji Dergisi, vol. 3, no. 1, 2018, pp. 1-9.
Vancouver Çelik E, Doğramacı AÇ. İNFANTİL HEMANJİYOM TEDAVİSİNDE BETA BLOKERLER. GDD. 2018;3(1):1-9.